Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Jan 30, 2021
Product Development

ALS looks up as clinical pipeline explodes

Three late-stage readouts this year and multiple mechanisms in the clinic could lift the lid on ALS treatments
BioCentury | Apr 20, 2018
Clinical News

CHMP rebuffs AB Science’s masitinib in ALS

BioCentury | Apr 19, 2018
Company News

CHMP rebuffs AB Science’s masitinib in ALS

BioCentury | Sep 15, 2017
Company News

CHMP issues negative opinions

BioCentury | May 19, 2017
Clinical News

AB Science reveals masitinib data in ALS trial

Items per page:
1 - 10 of 63